Jefferies Financial Group Lowers Kura Oncology (NASDAQ:KURA) Price Target to $28.00

Kura Oncology (NASDAQ:KURA) had its price objective reduced by Jefferies Financial Group from $32.00 to $28.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently commented on KURA. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday, November 19th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Wedbush reiterated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $10.80 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The business’s 50 day simple moving average is $17.88 and its two-hundred day simple moving average is $19.67. The stock has a market capitalization of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86. Kura Oncology has a one year low of $9.06 and a one year high of $24.17.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. SG Americas Securities LLC purchased a new stake in Kura Oncology in the first quarter worth $110,000. ProShare Advisors LLC grew its stake in Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares during the period. Vanguard Group Inc. grew its stake in shares of Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after acquiring an additional 870,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Kura Oncology by 17.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after acquiring an additional 2,940 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.